1. Asciminib vs bosutinib in CML patients pretreated with ≥2 tyrosine kinase inhibitors: Results from the Japanese subgroup analysis of ASCEMBL study. (27th September 2022) Authors: Yuda, Junichiro; Doki, Noriko; Matsuoka, Hiroshi; Yokota, Takafumi; Tomita, Akihiro; Takahashi, Naoto; Matsumura, Itaru; Kubo, Kohmei; Goto, Tatsunori; Kirito, Keita; Maki, Akio; Aoki, Makoto; Allepuz, Alex; Minami, Yosuke Journal: Cancer medicine Issue: Volume 12:Number 3(2023) Page Start: 2990 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗